Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “sector perform” rating restated by investment analysts at Royal Bank of Canada in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $2.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target suggests a potential upside of 134.19% from the company’s current price.
A number of other research firms have also recently issued reports on SGMO. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research report on Monday, January 27th. Wells Fargo & Company cut their price objective on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 31st. Jefferies Financial Group dropped their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. Truist Financial lowered their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Finally, StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $5.17.
View Our Latest Research Report on Sangamo Therapeutics
Sangamo Therapeutics Stock Down 15.4 %
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last released its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.70 million. As a group, equities analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. E Fund Management Co. Ltd. purchased a new stake in Sangamo Therapeutics during the fourth quarter worth $25,000. JPMorgan Chase & Co. grew its position in Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 21,793 shares during the period. PNC Financial Services Group Inc. grew its position in Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 25,000 shares during the period. SBI Securities Co. Ltd. acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at approximately $28,000. Finally, Shelton Wealth Management LLC purchased a new position in Sangamo Therapeutics during the fourth quarter valued at $29,000. Institutional investors own 56.93% of the company’s stock.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Recommended Stories
- Five stocks we like better than Sangamo Therapeutics
- How to Use the MarketBeat Dividend Calculator
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 3 Must-Own Stocks to Build Wealth This Decade
- What is a Death Cross in Stocks?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.